Evidence map›Paper›PMID 40426980›Full record

ReviewBiomedicines2025

HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis.

Hanna Miski, Kamila Krupa, Michał Piotr Budzik, Andrzej Deptała, Anna Badowska-Kozakiewicz

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hanna MiskiStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Kamila KrupaStudents' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0009-0006-1122-6445
Michał Piotr BudzikDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0001-6222-9079
Andrzej DeptałaDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0003-2640-2043
Anna Badowska-KozakiewiczDepartment of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.ORCID 0000-0002-4990-8760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

brain metastasisCNSHER2-positive breast cancermetastatic breast cancertrastuzumabtrastuzumab emtansine

Identifiers

PMID40426980
PMCPMC12109299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.